Interferon alfacon 1 inhibits SARS-CoV infection in human bronchial epithelial Calu-3 cells.
Identifieur interne : 001B72 ( PubMed/Corpus ); précédent : 001B71; suivant : 001B73Interferon alfacon 1 inhibits SARS-CoV infection in human bronchial epithelial Calu-3 cells.
Auteurs : Yohichi Kumaki ; Craig W. Day ; Miles K. Wandersee ; Bradley P. Schow ; Justin S. Madsen ; Dixon Grant ; Jason P. Roth ; Donald F. Smee ; Lawrence M. Blatt ; Dale L. BarnardSource :
- Biochemical and biophysical research communications [ 1090-2104 ] ; 2008.
English descriptors
- KwdEn :
- Animals, Antiviral Agents (pharmacology), Antiviral Agents (therapeutic use), Bronchi (virology), Cell Line, Cell Line, Tumor, Humans, Interferon Type I (pharmacology), Interferon Type I (therapeutic use), Interferon-alpha, Recombinant Proteins, Respiratory Mucosa (virology), SARS Virus (drug effects), SARS Virus (physiology), Severe Acute Respiratory Syndrome (drug therapy), Severe Acute Respiratory Syndrome (virology), Virus Replication (drug effects).
- MESH :
- chemical , pharmacology : Antiviral Agents, Interferon Type I.
- chemical , therapeutic use : Antiviral Agents, Interferon Type I.
- drug effects : SARS Virus, Virus Replication.
- drug therapy : Severe Acute Respiratory Syndrome.
- physiology : SARS Virus.
- virology : Bronchi, Respiratory Mucosa, Severe Acute Respiratory Syndrome.
- Animals, Cell Line, Cell Line, Tumor, Humans, Interferon-alpha, Recombinant Proteins.
Abstract
The primary targets for SARS-CoV infection are the epithelial cells in the respiratory and intestinal tract. The angiotensin-converting enzyme 2 (ACE-2) has been identified as a functional receptor for SARS-CoV. ACE-2 has been shown to be expressed at the apical domain of polarized Calu-3 cells. In this report, interferon alfacon 1 was examined for inhibitory activities against SARS-CoV on human lung carcinoma epithelial Calu-3 cell line and the other three African green monkey kidney epithelial cell lines. Interferon alfacon 1 demonstrated significant antiviral activity in neutral red uptake assay and virus yield reduction assay. The data might provide an important insight into the mechanism of pathogenesis of SARS-CoV allowing further development of antiviral therapies for treating SARS infections.
DOI: 10.1016/j.bbrc.2008.04.006
PubMed: 18406349
Links to Exploration step
pubmed:18406349Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Interferon alfacon 1 inhibits SARS-CoV infection in human bronchial epithelial Calu-3 cells.</title>
<author><name sortKey="Kumaki, Yohichi" sort="Kumaki, Yohichi" uniqKey="Kumaki Y" first="Yohichi" last="Kumaki">Yohichi Kumaki</name>
<affiliation><nlm:affiliation>Institute for Antiviral Research, Department of Animal, Dairy and Veterinary Science, Utah State University, 5600 Old Main Hill, Logan, UT 84322-5600, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Day, Craig W" sort="Day, Craig W" uniqKey="Day C" first="Craig W" last="Day">Craig W. Day</name>
</author>
<author><name sortKey="Wandersee, Miles K" sort="Wandersee, Miles K" uniqKey="Wandersee M" first="Miles K" last="Wandersee">Miles K. Wandersee</name>
</author>
<author><name sortKey="Schow, Bradley P" sort="Schow, Bradley P" uniqKey="Schow B" first="Bradley P" last="Schow">Bradley P. Schow</name>
</author>
<author><name sortKey="Madsen, Justin S" sort="Madsen, Justin S" uniqKey="Madsen J" first="Justin S" last="Madsen">Justin S. Madsen</name>
</author>
<author><name sortKey="Grant, Dixon" sort="Grant, Dixon" uniqKey="Grant D" first="Dixon" last="Grant">Dixon Grant</name>
</author>
<author><name sortKey="Roth, Jason P" sort="Roth, Jason P" uniqKey="Roth J" first="Jason P" last="Roth">Jason P. Roth</name>
</author>
<author><name sortKey="Smee, Donald F" sort="Smee, Donald F" uniqKey="Smee D" first="Donald F" last="Smee">Donald F. Smee</name>
</author>
<author><name sortKey="Blatt, Lawrence M" sort="Blatt, Lawrence M" uniqKey="Blatt L" first="Lawrence M" last="Blatt">Lawrence M. Blatt</name>
</author>
<author><name sortKey="Barnard, Dale L" sort="Barnard, Dale L" uniqKey="Barnard D" first="Dale L" last="Barnard">Dale L. Barnard</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2008">2008</date>
<idno type="RBID">pubmed:18406349</idno>
<idno type="pmid">18406349</idno>
<idno type="doi">10.1016/j.bbrc.2008.04.006</idno>
<idno type="wicri:Area/PubMed/Corpus">001B72</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001B72</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Interferon alfacon 1 inhibits SARS-CoV infection in human bronchial epithelial Calu-3 cells.</title>
<author><name sortKey="Kumaki, Yohichi" sort="Kumaki, Yohichi" uniqKey="Kumaki Y" first="Yohichi" last="Kumaki">Yohichi Kumaki</name>
<affiliation><nlm:affiliation>Institute for Antiviral Research, Department of Animal, Dairy and Veterinary Science, Utah State University, 5600 Old Main Hill, Logan, UT 84322-5600, USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Day, Craig W" sort="Day, Craig W" uniqKey="Day C" first="Craig W" last="Day">Craig W. Day</name>
</author>
<author><name sortKey="Wandersee, Miles K" sort="Wandersee, Miles K" uniqKey="Wandersee M" first="Miles K" last="Wandersee">Miles K. Wandersee</name>
</author>
<author><name sortKey="Schow, Bradley P" sort="Schow, Bradley P" uniqKey="Schow B" first="Bradley P" last="Schow">Bradley P. Schow</name>
</author>
<author><name sortKey="Madsen, Justin S" sort="Madsen, Justin S" uniqKey="Madsen J" first="Justin S" last="Madsen">Justin S. Madsen</name>
</author>
<author><name sortKey="Grant, Dixon" sort="Grant, Dixon" uniqKey="Grant D" first="Dixon" last="Grant">Dixon Grant</name>
</author>
<author><name sortKey="Roth, Jason P" sort="Roth, Jason P" uniqKey="Roth J" first="Jason P" last="Roth">Jason P. Roth</name>
</author>
<author><name sortKey="Smee, Donald F" sort="Smee, Donald F" uniqKey="Smee D" first="Donald F" last="Smee">Donald F. Smee</name>
</author>
<author><name sortKey="Blatt, Lawrence M" sort="Blatt, Lawrence M" uniqKey="Blatt L" first="Lawrence M" last="Blatt">Lawrence M. Blatt</name>
</author>
<author><name sortKey="Barnard, Dale L" sort="Barnard, Dale L" uniqKey="Barnard D" first="Dale L" last="Barnard">Dale L. Barnard</name>
</author>
</analytic>
<series><title level="j">Biochemical and biophysical research communications</title>
<idno type="eISSN">1090-2104</idno>
<imprint><date when="2008" type="published">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Bronchi (virology)</term>
<term>Cell Line</term>
<term>Cell Line, Tumor</term>
<term>Humans</term>
<term>Interferon Type I (pharmacology)</term>
<term>Interferon Type I (therapeutic use)</term>
<term>Interferon-alpha</term>
<term>Recombinant Proteins</term>
<term>Respiratory Mucosa (virology)</term>
<term>SARS Virus (drug effects)</term>
<term>SARS Virus (physiology)</term>
<term>Severe Acute Respiratory Syndrome (drug therapy)</term>
<term>Severe Acute Respiratory Syndrome (virology)</term>
<term>Virus Replication (drug effects)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term>
<term>Interferon Type I</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term>
<term>Interferon Type I</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>SARS Virus</term>
<term>Virus Replication</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Bronchi</term>
<term>Respiratory Mucosa</term>
<term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Cell Line</term>
<term>Cell Line, Tumor</term>
<term>Humans</term>
<term>Interferon-alpha</term>
<term>Recombinant Proteins</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The primary targets for SARS-CoV infection are the epithelial cells in the respiratory and intestinal tract. The angiotensin-converting enzyme 2 (ACE-2) has been identified as a functional receptor for SARS-CoV. ACE-2 has been shown to be expressed at the apical domain of polarized Calu-3 cells. In this report, interferon alfacon 1 was examined for inhibitory activities against SARS-CoV on human lung carcinoma epithelial Calu-3 cell line and the other three African green monkey kidney epithelial cell lines. Interferon alfacon 1 demonstrated significant antiviral activity in neutral red uptake assay and virus yield reduction assay. The data might provide an important insight into the mechanism of pathogenesis of SARS-CoV allowing further development of antiviral therapies for treating SARS infections.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18406349</PMID>
<DateCompleted><Year>2008</Year>
<Month>06</Month>
<Day>03</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>03</Month>
<Day>31</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1090-2104</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>371</Volume>
<Issue>1</Issue>
<PubDate><Year>2008</Year>
<Month>Jun</Month>
<Day>20</Day>
</PubDate>
</JournalIssue>
<Title>Biochemical and biophysical research communications</Title>
<ISOAbbreviation>Biochem. Biophys. Res. Commun.</ISOAbbreviation>
</Journal>
<ArticleTitle>Interferon alfacon 1 inhibits SARS-CoV infection in human bronchial epithelial Calu-3 cells.</ArticleTitle>
<Pagination><MedlinePgn>110-3</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbrc.2008.04.006</ELocationID>
<Abstract><AbstractText>The primary targets for SARS-CoV infection are the epithelial cells in the respiratory and intestinal tract. The angiotensin-converting enzyme 2 (ACE-2) has been identified as a functional receptor for SARS-CoV. ACE-2 has been shown to be expressed at the apical domain of polarized Calu-3 cells. In this report, interferon alfacon 1 was examined for inhibitory activities against SARS-CoV on human lung carcinoma epithelial Calu-3 cell line and the other three African green monkey kidney epithelial cell lines. Interferon alfacon 1 demonstrated significant antiviral activity in neutral red uptake assay and virus yield reduction assay. The data might provide an important insight into the mechanism of pathogenesis of SARS-CoV allowing further development of antiviral therapies for treating SARS infections.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kumaki</LastName>
<ForeName>Yohichi</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>Institute for Antiviral Research, Department of Animal, Dairy and Veterinary Science, Utah State University, 5600 Old Main Hill, Logan, UT 84322-5600, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Day</LastName>
<ForeName>Craig W</ForeName>
<Initials>CW</Initials>
</Author>
<Author ValidYN="Y"><LastName>Wandersee</LastName>
<ForeName>Miles K</ForeName>
<Initials>MK</Initials>
</Author>
<Author ValidYN="Y"><LastName>Schow</LastName>
<ForeName>Bradley P</ForeName>
<Initials>BP</Initials>
</Author>
<Author ValidYN="Y"><LastName>Madsen</LastName>
<ForeName>Justin S</ForeName>
<Initials>JS</Initials>
</Author>
<Author ValidYN="Y"><LastName>Grant</LastName>
<ForeName>Dixon</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y"><LastName>Roth</LastName>
<ForeName>Jason P</ForeName>
<Initials>JP</Initials>
</Author>
<Author ValidYN="Y"><LastName>Smee</LastName>
<ForeName>Donald F</ForeName>
<Initials>DF</Initials>
</Author>
<Author ValidYN="Y"><LastName>Blatt</LastName>
<ForeName>Lawrence M</ForeName>
<Initials>LM</Initials>
</Author>
<Author ValidYN="Y"><LastName>Barnard</LastName>
<ForeName>Dale L</ForeName>
<Initials>DL</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>N01 AI015435</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>N01-A1-30048</GrantID>
<Agency>PHS HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>N01-AI-15354</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2008</Year>
<Month>04</Month>
<Day>10</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Biochem Biophys Res Commun</MedlineTA>
<NlmUniqueID>0372516</NlmUniqueID>
<ISSNLinking>0006-291X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007370">Interferon Type I</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>56588OP40D</RegistryNumber>
<NameOfSubstance UI="C050739">interferon alfacon-1</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001980" MajorTopicYN="N">Bronchi</DescriptorName>
<QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007370" MajorTopicYN="N">Interferon Type I</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016898" MajorTopicYN="N">Interferon-alpha</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020545" MajorTopicYN="N">Respiratory Mucosa</DescriptorName>
<QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year>
<Month>03</Month>
<Day>28</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2008</Year>
<Month>04</Month>
<Day>02</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2008</Year>
<Month>4</Month>
<Day>15</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2008</Year>
<Month>6</Month>
<Day>5</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2008</Year>
<Month>4</Month>
<Day>15</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">18406349</ArticleId>
<ArticleId IdType="pii">S0006-291X(08)00661-X</ArticleId>
<ArticleId IdType="doi">10.1016/j.bbrc.2008.04.006</ArticleId>
<ArticleId IdType="pmc">PMC2441846</ArticleId>
<ArticleId IdType="mid">NIHMS51641</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15150417</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Science. 2003 Oct 10;302(5643):276-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12958366</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antivir Chem Chemother. 2006;17(5):275-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17176632</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2005 Aug;79(15):9470-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16014910</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Science. 2003 Jun 13;300(5626):1763-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12746549</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13190-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14585926</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Hepatology. 1997 Sep;26(3):747-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9303508</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antiviral Res. 2006 Aug;71(1):53-63</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16621037</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet. 2003 Jun 14;361(9374):2045-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12814717</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Gene Ther. 2006 Mar;13(6):532-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16177819</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1977-85</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12671062</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>JAMA. 2003 Dec 24;290(24):3222-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14693875</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Am J Respir Crit Care Med. 2003 Dec 15;168(12):1449-56</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12947028</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1953-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12690092</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>JAMA. 2003 Jun 4;289(21):2801-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12734147</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Respir Med. 2003 Apr;97(4):382-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12693798</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc R Soc Lond B Biol Sci. 1957 Sep 12;147(927):268-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">13465721</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Gen Virol. 2006 Jun;87(Pt 6):1691-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16690935</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Emerg Infect Dis. 2003 Sep;9(9):1064-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14519241</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet. 2003 May 24;361(9371):1767-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12781535</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2005 Mar;79(6):3846-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15731278</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antiviral Res. 2006 Feb;69(2):70-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16337697</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Curr Opin Investig Drugs. 2004 Feb;5(2):179-85</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15043392</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nature. 2003 Nov 27;426(6965):450-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14647384</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Am J Respir Cell Mol Biol. 2004 Mar;30(3):251-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14969997</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet. 2003 Jul 26;362(9380):293-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12892961</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Hepatology. 1998 Apr;27(4):1136-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9537455</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Invest New Drugs. 1990 Nov;8(4):347-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2084068</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antiviral Res. 2005 Jun;66(2-3):99-102</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15911026</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antivir Chem Chemother. 2004 Jan;15(1):15-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15074711</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc R Soc Lond B Biol Sci. 1957 Sep 12;147(927):258-67</Citation>
<ArticleIdList><ArticleId IdType="pubmed">13465720</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2536-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14983044</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet. 2003 Apr 19;361(9366):1319-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12711465</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B72 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001B72 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:18406349 |texte= Interferon alfacon 1 inhibits SARS-CoV infection in human bronchial epithelial Calu-3 cells. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:18406349" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a SrasV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |